Actinium Pharmaceuticals (ATNM) Stock Statistics & Valuation Metrics

Actinium Pharmaceuticals has a market cap or net worth of $55.84M. The enterprise value is ―.

Actinium Pharmaceuticals has 31,195,890 shares outstanding. The number of shares has decreased by -2.65% in one year.

Actinium Pharmaceuticals’s return on equity (ROE) is -1.34 and return on invested capital (ROIC) is -70.65%.

The current PE Ratio of Actinium Pharmaceuticals is -2.77. Actinium Pharmaceuticals’s PEG ratio is -0.11.

In the last 12 months, Actinium Pharmaceuticals had revenue of 81.00K and earned -48.82M in profits. Earnings per share was -1.83.

In the last 12 months, operating cash flow was -34.81M and capital expenditures -11.00K, giving a free cash flow of -34.82M billion.

Actinium Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Actinium Pharmaceuticals upcoming earnings date is Nov 24, 2025, TBA Not Confirmed.

Actinium Pharmaceuticals as a current ratio of 9.21, with Debt / Equity ratio of 4.48%

In the past 12 months, Actinium Pharmaceuticals has paid 0.00 in taxes.

Actinium Pharmaceuticals EV to EBITDA ratio is -1.18, with an EV/FCF ratio of -1.28.

Actinium Pharmaceuticals has $78.66M in cash and marketable securities with $1.71M in debt, giving a net cash position of -$76.95M billion.

Gross margin is -645.68%, with operating margin of -64098.77%, and net profit margin of -60269.14%.

The average price target for Actinium Pharmaceuticals is $6.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy